Valproic Acid and Bevacizumab in Patients With Advanced Cancer

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT00530907
Phase
PHASE1
Status
Completed

Conditions

  • Advanced Cancer

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Valproic Acid — DRUG
    5.3 mg/kg by mouth daily x 28 days
  • Bevacizumab — DRUG
    2.5 mg/kg by vein over 90 minutes every 2 weeks

Study Details

The goal of this clinical research study is to find the highest tolerable dose of bevacizumab in combination with valproic acid that can be given to patients with advanced cancer that has not responded to standard treatment or where there is no standard treatment for the disease. The safety of this drug combination will also be studied.

Key Dates

First listed
Sep 18, 2007
Start date
Jun 30, 2007
Status verified
Nov 2013
Primary completion
Nov 30, 2013
Completion
Nov 30, 2013

Study Design

Enrollment
71 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Valproic Acid + Bevacizumab
    Valproic acid administered at a dose of 5.3 mg/Kg/day on days 1 - 28. Depending on the calculated dose, patients will take capsules once or twice a day per mouth. Bevacizumab administered at a dose of 2.5 mg/kg by vein every 2 weeks.

Primary Outcome Measure

Highest tolerable dose of bevacizumab in combination with valproic acid [ Time Frame: 28 day cycle ]

Locations (1)

FacilityCityStateZIPSite coordinators
UT MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Houston, TX

By research site
UT MD Anderson Cancer Center· Houston, TX

Related Studies